Bafna Pharmaceuticals is currently trading at its upper circuit limit of Rs. 24.65, up by 1.15 points or 4.89% from its previous closing of Rs. 23.50 on the BSE.
The scrip opened at Rs. 24.65 and has touched a high and low of Rs. 24.65 and Rs. 24.65 respectively. So far 147 shares were traded on the counter.
The BSE group 'T' stock of face value Rs. 10 has touched a 52 week high of Rs. 32.40 on 06-Sep-2017 and a 52 week low of Rs. 20.00 on 14-Aug-2017.
Last one week high and low of the scrip stood at Rs. 24.70 and Rs. 23.15 respectively. The current market cap of the company is Rs. 58.31 crore.
The promoters holding in the company stood at 26.36%, while Non-Institutions held 73.64% stake in the company.
Bafna Pharmaceuticals’ facility has received renewal approval as per the Guidelines of European Good Manufacturing Practices (EUGMP) from Medicines and Healthcare products Regulatory Agency (MHRA).
Bafna Pharmaceuticals is engaged in the production of tablets, capsule and oral syrup.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1532.00 |
Dr. Reddys Lab | 5780.70 |
Cipla | 1442.00 |
Zydus Lifesciences | 1088.45 |
Lupin | 1683.50 |
View more.. |